"10.1371_journal.pone.0105638","plos one","2014-08-28T00:00:00Z","Sue Sha; Damayanthi Devineni; Atalanta Ghosh; David Polidori; Marcus Hompesch; Sabine Arnolds; Linda Morrow; Heike Spitzer; Keith Demarest; Paul Rothenberg","Janssen Research & Development, LLC, Raritan, NJ, United States of America; Janssen Research & Development, LLC, San Diego, CA, United States of America; Profil Institute for Clinical Research, Chula Vista, CA, United States of America; Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany","Conceived and designed the experiments: SS DD AG MH SA KD PR. Performed the experiments: SS MH SA LM HS. Analyzed the data: DD AG DP. Contributed to the writing of the manuscript: SS DP PR. Other: SS DD AG DP MH SA LM HS KD PR.","The authors have the following interests. This study was sponsored by Janssen Research & Development, LLC. Editorial support was provided by Cherie Koch, PhD, of MedErgy, and was funded by Janssen Global Services, LLC. Canagliflozin has been developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation. The funding organization was involved in the design, data collection and analysis, and preparation of the manuscript for publication. Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Keith Demarest and Paul Rothenberg are employed by Janssen Research & Development. Marcus Hompesch and Linda Morrow are employed by Profil Institute for Clinical Research and Sabine Arnolds and Heike Spitzer by Profil Institut für Stoffwechselforschung GmbH. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","08","Sue Sha","SS",10,TRUE,7,5,3,NA,TRUE,FALSE,FALSE,0,NA,FALSE
